ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Novel Treatments, Medical Community, Diagnosis and Treatment, Clinical Research, Updates from Conferences, Entities of Cancer Our MBClife Novel Treatments, Medical Community, Diagnosis and Treatment, Clinical Research, Updates from Conferences, Entities of Cancer Our MBClife

ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?

Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.

Read More
Road to a Cure - Dr. Sara Hurvitz
Novel Treatments, Medical Community, Challenges and Barriers, Clinical Research, Obstacles to Better Outcomes, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat Our MBClife Novel Treatments, Medical Community, Challenges and Barriers, Clinical Research, Obstacles to Better Outcomes, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat Our MBClife

Road to a Cure - Dr. Sara Hurvitz

The Road to a Cure series gets on the redeye to LA to have Senior Producer and Co-host, Victoria Goldberg and co-host Kate Pfitzer speak with Dr. Sara Hurvitz. She talks about her perspective on where we are as we work for a cure, the HER2+ studies she is excited about, and other research that is intriguing as it relates to all subtypes

Read More